Eli Lilly and Co (LLY)

83.04
1.24 1.47
NYSE : Health Care
Prev Close 84.28
Open 84.28
Day Low/High 83.04 / 84.33
52 Wk Low/High 64.18 / 86.72
Volume 2.36M
Avg Volume 3.90M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 92.56B
EPS 2.60
P/E Ratio 40.53
Div & Yield 2.08 (2.50%)

Latest News

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Eli Lilly And Company Unveils Expanded Biotechnology Center In San Diego

New facility and improved technology capabilities part of $850 million U.S. capital investment for 2017

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

On Betting Against the Bonds and Panicking off the Fed: Jim Cramer's Best Blog

On Betting Against the Bonds and Panicking off the Fed: Jim Cramer's Best Blog

Jim Cramer discusses bonds and also talks about why panicking off the Fed is a superbad idea.

Cramer: You Can't Bet Against the Bonds

Cramer: You Can't Bet Against the Bonds

A rotation that started as the minor chord of the rotational symphony and is now the major one.

New Safety And Long-Term Efficacy Data From Baricitinib Clinical Trials In Patients With Moderate-to-Severe Rheumatoid Arthritis Presented At EULAR 2017

- Pooled analysis of eight clinical trials shows no difference in serious infection events compared to placebo

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Lilly To Present New Data On Olumiant® (baricitinib) In Rheumatoid Arthritis And Taltz® (ixekizumab) In Psoriatic Arthritis At The Annual European Congress Of Rheumatology (EULAR 2017)

Lilly to share 31 abstracts, including 27 abstracts detailing safety, efficacy and patient outcomes data for Olumiant and Taltz

GOP Leader Floats 'Very Gradual' Phase-In Plan for Border Adjustment Tax

GOP Leader Floats 'Very Gradual' Phase-In Plan for Border Adjustment Tax

Rep. Kevin Brady said the plan resolves major challenges, forging on instead of dropping the idea as some fellow GOP leaders have suggested.

Jardiance® (empagliflozin) Analysis Reinforces Established Safety Profile

- Analysis of 12,500 adults with type 2 diabetes from 19 studies showed amputations and fractures were not increased with Jardiance compared with placebo

Pfizer, Eli Lilly Granted Accelerated Review for Non-Opiod Pain Relief Drug

Pfizer, Eli Lilly Granted Accelerated Review for Non-Opiod Pain Relief Drug

The FDA approval comes amidst America's struggle with an opioid epidemic.

Pfizer And Lilly Receive FDA Fast Track Designation For Tanezumab

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.

Elanco Releases First-Ever Corporate Social Responsibility Impact Report

Report highlights improved food security of nearly 840,000 families and expansion of pet therapy program globally

Jardiance® (empagliflozin) Tablets To Be Studied In Chronic Kidney Disease

- New outcome study to evaluate the effect of JARDIANCE for the treatment of people with chronic kidney disease

Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags

Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags

Newly released neurotransmitter research could open up a $8 - $10 billion market as early as next year.

Amgen Wants to Boost Label on Powerhouse Repatha

Amgen Wants to Boost Label on Powerhouse Repatha

The day before Amgen appeared in court, the biopharma giant announced a submission to change its label on powerhouse drug Repatha.

Cramer: 15 Stocks to Buy for the Triathlon of Fear Coming on Super-Thursday

Cramer: 15 Stocks to Buy for the Triathlon of Fear Coming on Super-Thursday

The handwringers will be out in full force. Their fear creates buying opportunities.

Lilly Builds Upon Body Of Data For Abemaciclib With Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival In Advanced Breast Cancer

- Abemaciclib plus fulvestrant significantly improved efficacy outcomes over placebo plus fulvestrant

Bearish Bets: A Drug Giant, a Tea Seller and Other Stocks That Look Good Short

FARM, FET, POST, LLY and SPA recently were downgraded by TheStreet's Quant Ratings.

Boehringer Ingelheim And Lilly Diabetes Alliance To Present 33 Abstracts At The American Diabetes Association's 77th Scientific Sessions®

- Clinical and pre-clinical data will showcase breadth of treatment options

Derica Rice To Retire As Lilly Chief Financial Officer

Rice will continue in position through 2017, successor named at a later date